about
Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients.The role of recombinant erythropoietin in childhood cancer.Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents--a comprehensive review of biology, clinical course and treatment options.Dynamic contrast-enhanced MRI improves accuracy for detecting focal splenic involvement in children and adolescents with Hodgkin disease.Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma - A review of clinical outcome based on the histological variants.Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group.Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups.High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.Identification and molecular characterisation of a CALM-AF10 fusion in acute megakaryoblastic leukaemia.Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma.LG-70DISSEMINATED LOW GRADE GLIOMA IN CHILDREN AND ADOLESCENTS- A RETROSPECTIVE REVIEW OF TREATMENT OUTCOME IN A SINGLE CENTRE.Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI?Evaluation of treatment response using integrated 18F-labeled choline positron emission tomography/magnetic resonance imaging in adolescents with intracranial non-germinomatous germ cell tumours.Variant histology nodular lymphocyte predominant Hodgkin lymphoma - a route to transformation?Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma.18F-fluoroethylcholine (18F-Cho) PET/MRI functional parameters in pediatric astrocytic brain tumors.Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging.Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.Thyrotoxicosis After Matched Unrelated Bone Marrow TransplantationHypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastomaTreatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin’s lymphoma – An Anglo-French collaborative reportHodgkin’s lymphoma in children aged 5 years or less – The United Kingdom experienceOutcome After Autologous Hemopoietic Stem Cell Transplantation in Relapsed or Refractory Childhood Hodgkin DiseaseAdenovirus infection after pediatric bone marrow transplantation: is treatment always necessary?Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantationLocal therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG)Does histology influence outcome in childhood Hodgkin's disease? Results from the United Kingdom Children's Cancer Study GroupRoutine blood counts in children with acute lymphoblastic leukaemia after completion of therapy: are they necessary?A limited role for VEEP (vincristine, etoposide, epirubicin, prednisolone) chemotherapy in childhood Hodgkin's diseaseA randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHLAminoglycoside-induced deafness during treatment of acute leukaemiaHospital ventilation, heat and humidity: risk of fungal and other infectionsLoeffler myocarditis in pre-B acute lymphoblastic leukaemia with t(5;14)(q31;q32)The role of routine surveillance for silent central nervous system relapse in children with acute lymphoblastic leukaemia
P50
Q35057430-BF8D490F-06BD-420C-8EEA-66B53E836887Q37096399-BABCC795-D455-4099-9DB4-E33581E80AC6Q38044928-22508A61-F364-43BD-878F-2FFD020126E3Q38078804-6514FFD1-5FF5-4D10-B649-4088C213E83CQ38538641-C21B7A28-06D3-4DCC-B8DE-EB70D81972A9Q39904031-F170FEF6-9F34-4587-A1F1-D75650A13D3CQ40326133-3992BEEF-7240-4A2A-AD9A-AE1BD31F2B4BQ42545990-58934670-3869-4FB7-9608-F8FAE4A4D4DFQ43647230-3D63B589-BDB4-49FF-8225-EC54860B91F1Q43721830-3BFE58E0-6678-4488-9FD1-A7FF84CC7244Q44275954-3B3E8995-80E4-492A-8F88-8464E774CDE7Q44830954-09CFE8A1-887C-40D1-BC77-E4FD4EA6C80AQ45951350-6D709434-C042-4058-83CA-042C5B1D9AEFQ46579579-9237AE64-7873-4779-AC37-BE794D91FCD5Q48239895-6E726E7F-5CFE-4808-AA08-1524A28A54B2Q48335812-520D6AF2-E5D0-47F3-B611-78E5ECF2DEB8Q48356700-E397E724-0259-466D-BA4E-B3962020D026Q48564640-7EA361E0-C181-4109-A566-4AA4C2375533Q51576034-7F939F8D-05C1-4D0D-A855-38D5CA01C394Q51740308-3CD43F5A-9A89-4D1D-AC9B-EC187EB9FF11Q57841678-7FC911A9-C0EA-4D75-B1C8-3A1CAF9B2A93Q58005054-81D097E1-F78C-48BB-A435-DD0FE28AC7AEQ58325849-31AF966D-CF30-4CE1-A951-81CFA2FB41CCQ58325942-03CBD8DB-5E26-4800-AFC7-1E2272EE6824Q58325988-E103E095-3AE3-4923-8C0C-7EC3C0DA1239Q64378760-F6871241-0C69-4CAE-B511-D18540B41B48Q73309845-8BFD6FE7-C5E6-4832-B63D-59D2B066CA84Q73446743-D5F30E61-B11C-4F93-8EFF-F7AEFAD52ACEQ73494811-7A4DA894-19E4-459F-BF42-A0EB8D37EAA3Q73701956-B2F47D7D-35A8-499C-863B-B6A1A2296509Q74591577-D024EB78-BC42-4E7F-894B-1AC3AF2C1D71Q77551165-FA638D5D-B03F-4A04-8975-4EAF3536E0A2Q82982081-B54E4017-CA8F-457B-9531-25422682A6C8Q83185633-5066EEF6-EC6B-4FFA-9A08-A449CD98BA0AQ83709858-F75D4FCC-5F1E-4CCB-B1C4-D89FA513A256Q84875858-9304233A-DE5B-4904-B66B-9489D6D32308
P50
description
researcher, ORCID id # 0000-0001-9885-5776
@en
wetenschapper
@nl
name
Ananth Shankar
@ast
Ananth Shankar
@en
Ananth Shankar
@es
Ananth Shankar
@nl
অনন্ত শংকর
@bn
type
label
Ananth Shankar
@ast
Ananth Shankar
@en
Ananth Shankar
@es
Ananth Shankar
@nl
অনন্ত শংকর
@bn
prefLabel
Ananth Shankar
@ast
Ananth Shankar
@en
Ananth Shankar
@es
Ananth Shankar
@nl
অনন্ত শংকর
@bn
P106
P31
P496
0000-0001-9885-5776